US President Donald Trump signed an executive order aimed at forcing drug companies to reduce prices, which has created ripples in the global pharmaceutical market. The order mandates that pharmaceutical firms either voluntarily reduce drug prices or face regulatory action. The policy is rooted in the idea that Americans should not pay more than citizens in other developed nations for the same medicines.

Trump’s “Most-Favoured-Nation” pricing policy seeks to align drug prices in the US with the lowest prices paid in other Organisation for Economic Co-operation and Development (OECD) countries. The US currently pays more than three times the amount paid in peer nations, and Trump claimed that the US is subsidising about 75% of global pharma profits.

Indian Drugmakers: Underperformance Amid Broader Market Gains

While Wall Street cheered the executive order, especially because it wasn't as harsh as expected, India’s pharmaceutical giants like Sun Pharma, Dr. Reddy’s, Cipla, Biocon, and Aurobindo Pharma did not perform as strongly on a broadly positive day for the Indian stock market. The Nifty Pharma index opened lower but recovered slightly, ending just above the flatline, lagging behind the broader market rally.

Investors in Indian pharma stocks reacted cautiously, primarily due to the uncertainty over how this order might affect pricing power in the US — a key export market for these companies.

No Direct Impact Yet on Generic Drugs

The executive order doesn't directly impact the pricing of generic drugs, which forms the bulk of exports for Indian pharma firms. However, the ambiguity around enforcement mechanisms and potential follow-up actions keeps the sector on edge.

Additionally, the threat of tariffs or further regulatory barriers looms large, especially since India is a significant supplier of affordable generic medicines to the US market. Any disruption in this supply chain or a price cap could affect margins and export volumes.

US Pharma Stocks Rally on Softer Than Expected Order

Ironically, while Indian pharma stocks underperformed, major US drugmakers such as Pfizer, Eli Lilly, Amgen, and Sanofi ended the day higher. The market had feared more aggressive price slashes, which didn’t materialise. This “less severe than expected” executive order was interpreted positively by the Street, as it seemed to be more of a political move to get pharma companies to the negotiating table rather than impose outright cuts.

Regulatory Environment and Investor Sentiment

The global pharma sector is now caught in a balancing act. On one side, governments — especially in large markets like the US — are seeking to reduce patient costs, while on the other, companies are trying to preserve margins and fund their extensive R&D pipelines.

For Indian drugmakers, the biggest concern is the uncertainty surrounding US policy directions. If the current administration goes ahead with enforcing “Most-Favoured-Nation” pricing in a stringent manner, it could mean downward pressure on revenue for Indian firms dependent on exports to the US.

Strategic Diversification Could Be Key

Many Indian pharma companies have been diversifying their geographical presence and increasing investments in biosimilars, domestic branded formulations, and emerging markets. This strategy might help cushion the impact of policy-led volatility in the US market.

Moreover, companies like Cipla and Biocon have already been expanding their presence in newer therapeutic areas, such as respiratory and biologics. These areas may be less prone to aggressive price regulation due to their complexity and limited competition.

Nifty Pharma’s Performance Snapshot

• Nifty Pharma index opened with a gap down following news of the executive order.

• During the session, most index constituents recovered, but the index ended up underperforming the broader Nifty 50 index.

• This is notable as the broader markets rallied strongly on Monday, led by gains in the tech, auto, and banking sectors.

What Lies Ahead?

As the executive order unfolds into actionable policy, Indian drugmakers will have to closely watch for developments such as tariff decisions, enforcement mechanisms, and pricing benchmarks. The US election cycle adds another layer of unpredictability, as healthcare continues to be a major campaign issue.

For investors, caution will likely dominate the short term, especially in stocks with heavy reliance on US generics or biosimilar exports. However, the long-term fundamentals of Indian pharma remain strong, driven by cost efficiency, robust pipelines, and global credibility in manufacturing.

Conclusion

In summary, while Trump’s executive order may not have had an immediate negative impact on Indian pharma firms, the longer-term implications of potential US drug pricing reforms remain a concern. Investors are advised to stay updated and cautious, especially in companies with significant exposure to the US healthcare system.

The Upcoming IPOs in this week and coming weeks are Integrity Belrise Industries, Integrity Infrabuild Developers, Accretion Pharmaceuticals, Wagons Learning.

The Current active IPO are Virtual Galaxy Infotech.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.